Skip to main content

Month: August 2023

Saputo Reports Financial Results for the First Quarter of Fiscal 2024 Ended June 30, 2023

MONTRÉAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the first quarter of fiscal 2024, which ended on June 30, 2023. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS). “Our business delivered solid results in the first quarter in the face of significant commodity market headwinds and lower consumer demand. We had another quarter of adjusted EBITDA and margin growth with a strong performance in our Canada Sector, significant operational improvements in our Australia division, and more operational stability in the USA Sector. Despite unprecedented market conditions, the underlying health of...

Continue reading

D-BOX Technologies’ First Quarter Highlighted by Strong Growth in Revenue and Profitability

First quarter caps best four consecutive quarters on recordAdjusted EBITDA* increased 108% to $1.3 million year-over-year Total revenues grew 47% to $10.5 million year-over-year System sales revenues increased 73% to $7.5 million year-over-year Rights for use, rental and maintenance revenues of $3.0 million – best on record Net income of $0.5 million, or $0.002 per shareMONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, today reported financial results for the first quarter ended June 30, 2023. All dollar amounts are expressed in Canadian currency. “We continue to execute our plan for delivering profitable growth,” said Sébastien Mailhot, President and Chief Executive Officer of D-BOX. “Following the strong...

Continue reading

Mattr Announces Second Quarter 2023 Results

TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Shawcor Ltd., dba Mattr Infratech (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2023. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (MD&A) and interim consolidated financial statements for the three and six months ended June 30, 2023, which are available on the Company’s website and at www.sedarplus.ca. Highlights from the second quarter include1:On a consolidated basis, revenue was $401 million, income from operations was $28 million and Adjusted EBITDA was $67 million; Composite Technologies (formerly known as Composite Systems) segment set a new quarterly revenue record, increasing by 11% to $150 million compared to $135 million in...

Continue reading

Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided a business update. “Following FDA clearance of our IND for PH-762, we are moving forward with plans for a clinical trial for stages one, two and four of cutaneous squamous cell (cSCC), stage four melanoma and Merkel cell,” said Robert Bitterman, President and CEO. The initial multi-center, dose-escalating, Phase 1b clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose...

Continue reading

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

– Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer – – Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 – – Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to an additional $250 million in milestone payments upon the achievement of certain return thresholds – – As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares of Vaxcyte common stock valued at $33.3 million, which together provide a projected cash runway into the first half of 2025...

Continue reading

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update. “We continue to make progress advancing our lead candidate AL102, which is being evaluated in the ongoing Phase 3 registration-enabling RINGSIDE for the treatment of desmoid tumors. We recently concluded an instructive and successful End-of-Phase-2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and have...

Continue reading

Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights

Topline Results from Four CNS Clinical Trials Expected in the Third and Fourth Quarters of 2023 Fibromyalgia Topline Results Expected in the Fourth Quarter of 2023 for Phase 3 Potentially NDA-Enabling Study of the Centrally-Acting Non-Opioid Analgesic TNX-102 SL Completed Strategic Acquisition of Two Marketed Acute Migraine Products: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) CHATHAM, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent operational highlights. “We have recently completed enrollment in four clinical trials for central nervous system (CNS) indications, representing our continuing...

Continue reading

Sienna Senior Living Inc. Reports Strong Second Quarter 2023 Financial Results as Operating Fundamentals Continue to Improve

MARKHAM, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2023. The Consolidated Financial Statements and accompanying Management’s Discussion and Analysis (“MD&A”) are available on the Company’s website at www.siennaliving.ca and on SEDAR at www.sedar.com. Sienna’s strong second quarter underscores an improving operating environment in the senior living sector and highlights the significant growth potential in the Company’s business. “Our second quarter results emphasize the strength of our diversified portfolio, which is reflected in the notable improvements of many key performance indicators, including a 9.3% increase in our same property NOI,” said Nitin Jain, President and Chief Executive...

Continue reading

Wesdome Announces Second Quarter 2023 Financial Results

(All figures are stated in Canadian dollars unless otherwise noted.) TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX:WDOFF) (“Wesdome” or the “Company”) today announces second quarter (“Q2 2023”) financial results. Management will host a conference call tomorrow, Friday August 11, 2023, at 10:00 a.m. Eastern time to discuss the results. Dial-in details for the call can be found near the end of this press release. Second quarter 2023 highlightsPayable gold production in the second quarter of 2023 was 30,992 ounces at Cash costs per ounce of $1,743 (US$1,298) and all-in sustaining costs (“AISC”) per ounce of $2,238 (US$1,666). These results compared well relative to internal targets for the quarter and reflect consistent performance from Eagle River and the successful ongoing ramp-up of mining...

Continue reading

Consolidated Water Reports Second Quarter 2023 Revenue up 110% to $44.2 Million and Net Income of $7.3 Million or $0.46 per Diluted Share

GEORGE TOWN, Cayman Islands, Aug. 10, 2023 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, reported results for the second quarter ended June 30, 2023. All comparisons are to the same prior year period unless otherwise noted. The company will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). Second Quarter 2023 Financial HighlightsTotal revenue increased 110% to $44.2 million. Retail revenue increased 16% to $7.6 million. Services revenue increased 377% to $24.1 million, with recurring services revenue generated from operation and maintenance contracts up 11% to $3.9 million. Manufacturing revenue increased to $4.1 million.  Net income from continuing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.